American Leprosy Missions meets the 20 Standards for Charity Accountability.
American Leprosy Missions (ALM) covers costs of treating leprosy in countries in Africa and Asia that have the highest detection rates for the disease. The organization also funds reconstructive, cosmetic, and other surgical procedures to alleviate leprosy's damage to the body; provides physical therapy rehabilitation programs; and offers business start-up advice and job skill training to patients. In addition to research grants aimed at improving the screening and assessment of patients, ALM funds the development of a leprosy vaccine. At ALM-supported hospitals, health workers receive training in recognizing and treating leprosy. The organization also sponsors broadcasts and produces materials including books, brochures and posters for health clinics designed to teach recognition of early warning signs as well as reduce the fear and stigma associated with leprosy. ALM reports that it is currently carrying out a campaign against Buruli ulcer (a flesh-destroying bacterium closely related to leprosy) in Cote d'Ivoire, Ghana, Liberia and the Democratic Republic of the Congo.
For the year ended June 30, 2021, American Leprosy Missions's program expenses were:
Program services |
$18,940,313 |
Total Program Expenses: |
$18,940,313 |
-
Chief Executive
David W. Simmons, President and Chief Executive Officer
-
Compensation*
$225,636
-
Chair of the Board
Chris Hogue
-
Chair's Profession / Business Affiliation
Strategy Specialist, World Vision International
-
Board Size
9
-
Paid Staff Size
32
*2020 compensation includes annual salary and, if applicable, benefit plans, expense accounts, and other allowances.
Method(s) Used:
Direct mail appeals, Grant proposals, Internet, Invitations to fund raising events, Planned giving arrangements, Telephone appeals, Radio
Fundraising costs were 14% of related contributions. (Related contributions, which totaled $21,870,469 are donations received as a result of fundraising activities.)
This organization is tax-exempt under section 501(c) (3) of the Internal Revenue Code.It is eligible to receive contributions deductible as charitable donations for federal income tax purposes.
The following information is based on American Leprosy Missions's audited financial statements for the year ended June 30, 2021.
Source of Funds |
Contributions in-kind |
$13,735,003 |
Contributions and grants |
$7,062,240 |
Realized and net unrealized gain on investments, net |
$614,670 |
Legacies and bequests |
$518,690 |
Trust income |
$253,993 |
U.S. government grants |
$206,393 |
Investment return in excess of amount designated for current operations |
$166,371 |
Investment income, net |
$115,641 |
Special events |
$94,150 |
Other |
$876 |
Actuarial loss on annuities |
($6,765) |
Total Income |
$22,761,262 |
- Programs: 82%
- Fundraising: 13%
- Administrative: 5%
Total Income |
$22,761,262 |
Program expenses |
$18,940,313 |
Fundraising expenses |
$3,085,909 |
Administrative expenses |
$1,220,600 |
Other expenses |
$0 |
Total expenses: |
$23,246,822 |
Income in Excess of Expenses |
$-485,560 |
Beginning Net Assets |
$13,930,719 |
Other Changes In Net Assets |
$1,656,897 |
Ending Net Assets |
$15,102,056 |
Total Liabilities |
$479,241 |
Total Assets |
$15,581,297 |
Note 1: According to the audited financial statements for the year ended June 30, 2021, ALM had "other changes in net assets" of $1,656,897 for change in beneficial interest in perpetual trusts.
Note 2: Add in-kind note for $13,735,003 for medical supplies and ask for breakdown.